Background: Cytokine storm in COVID-19 is heterogenous. There are at least three
subtypes: cytokine release syndrome (CRS), macrophage activation syndrome (MAS), and …

Abstract Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …

Background The release of pro-inflammatory cytokines, resulting in cytokine storm
syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This …

Introduction: Corona virus is a group of viruses that cause diseases in mammals and birds.
In humans, these families of viruses can cause respiratory infections from a mild form to fatal …

Abstract Infection following SARS‐Co V‐2 leading to COVID‐19 disease is associated with
significant morbidity and mortality. The clinical entity, COVID‐19 cytokine storm syndrome …

Background Cytokine release syndrome (CRS), characterized by overproduction of
proinflammatory cytokines in the course of severe coronavirus disease 2019 (COVID-19) …

Objective Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …

Coronavirus disease 19 (COVID-19) which is caused by Severe Acute Respiratory
Syndrome Coronavirus-2 (SARS-CoV-2), has been a problem worldwide, particularly due to …

The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a
significant burden on hospitals and healthcare providers. The immune response to this …

Background We aimed to determine the impact of tocilizumab use on severe COVID-19
(coronavirus disease 19) pneumonia mortality. Methods We performed a multicentre …